{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:52:46Z","timestamp":1767135166976,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd012804","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000}}],"reference-count":99,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012804.pub2","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T21:42:37Z","timestamp":1576100557000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Anti-IL-12\/23p40 antibodies for maintenance of remission in Crohn's disease"],"prefix":"10.1002","volume":"2019","author":[{"given":"Sarah C","family":"Davies","sequence":"first","affiliation":[{"name":"University of Western Ontario; Schulich School of Medicine & Dentistry; London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; 100 Dundas Street, Suite 200 London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; 100 Dundas Street, Suite 200 London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; 100 Dundas Street, Suite 200 London ON Canada"},{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; 100 Dundas Street, Suite 200 London ON Canada"},{"name":"University of Western Ontario; Department of Medicine; London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"10.1002\/14651858.CD012804.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ecco-jcc\/jjw019.027","article-title":"Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's disease: results from the UNITI-1 and UNITI-2 studies","volume":"10","author":"Adedokun","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0002|cit2","first-page":"A3","article-title":"Exposure-response to SC ustekinumab in moderate-severe Crohn's disease: results from the IM-UNITI maintenance study","volume":"5","author":"Adedokun","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0003|cit3","first-page":"S408","article-title":"Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies","volume":"150","author":"Adedokun","year":"2016","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0004|cit4","first-page":"A308","article-title":"Response and remission after 16 weeks of ustekinumab\u2014an all patients analysis from the UNITI Crohn's studies","volume":"5","author":"Colombel","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1093\/ecco-jcc\/jjx180.408","article-title":"Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn's disease studies","volume":"12 (Suppl 1)","author":"Colombel","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0006|cit6","first-page":"S3","article-title":"Response and remission after 16 weeks of ustekinumab\u2014an all patients analysis from the UNITI Crohn's studies","volume":"113 (Suppl 1)","author":"Colombel","year":"2018","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.14309\/00000434-201710001-00718","article-title":"Response and remission after 16 weeks of ustekinumab: an all patients analysis from the UNITI Crohn's studies","volume":"112 (Suppl 1)","author":"Colombel","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0008|cit8","unstructured":"EUCTR2010-022760-12-NL A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab maintenance therapy in subjects with moderately to severely active Crohn\u2019s disease\u2014IMUNITI who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-022760-12-NL"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S595","DOI":"10.1016\/S0016-5085(17)32131-5","article-title":"Effect of maintenance ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease","volume":"152","author":"Feagan","year":"2017","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0010|cit10","first-page":"S359-60","article-title":"Effect of maintenance ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease","volume":"11","author":"Feagan","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"20","key":"10.1002\/14651858.CD012804.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/S0016-5085(18)32139-5","article-title":"Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: A post-hoc analysis of the Uniti trials","volume":"154","author":"Feagan","year":"2018","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1016\/S0016-5085(18)31602-0","article-title":"Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs placebo from the phase 3 UNITI Crohn's disease studies, by population","volume":"154","author":"Ghosh","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1093\/ecco-jcc\/jjx180.799","article-title":"Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn's disease studies, by population","volume":"12 (Suppl 1)","author":"Ghosh","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/ecco-jcc\/jjy222.804","article-title":"Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn's disease: results from IM-UNITI long-term extension through 2 years","volume":"13","author":"Ghosh","year":"2019","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1093\/ecco-jcc\/jjx180.313","article-title":"Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: a post-hoc analysis of the UNITI trials","volume":"12 (Suppl 1)","author":"Ghosh","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/S0016-5085(18)31558-0","article-title":"Impact of prior surgical history on efficacy with ustekinumab in Crohn's disease: A subgroup analysis of the phase 3 Uniti studies","volume":"154","author":"Hanauer","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0018|cit18","unstructured":"Hanauer SB Sandborn WJ Feagan BG Gasink C Jacobstein D Zou B IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease Journal of Crohn's and Colitis 10.1093\/ecco-jcc\/jjz110"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S1099","DOI":"10.1016\/S0016-5085(19)39709-4","article-title":"Identification of Risk Factors Associated with Loss of Response to Ustekinumab in Crohn's Disease","volume":"156","author":"Hanauer","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012804.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5217\/ir.2017.15.4.475","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies","volume":"15","author":"Hibi","year":"2017","journal-title":"Intestinal Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S595","DOI":"10.1016\/S0016-5085(17)32132-7","article-title":"Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease","volume":"152","author":"Li","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0022|cit22","first-page":"A123","article-title":"Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease","volume":"66 (Suppl 2)","author":"Li","year":"2017","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0023|cit23","first-page":"S314-5","article-title":"Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease","volume":"11","author":"Li","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"4","key":"10.1002\/14651858.CD012804.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1053\/j.gastro.2019.06.037","article-title":"Effects of ustekinumab on histologic disease activity in patients with Crohn's disease","volume":"157","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0016-5085(16)31326-9","article-title":"Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: results from uniti-1 induction, uniti-2 induction, and imuniti maintenance studies","volume":"150","author":"Li","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/ecco-jcc\/jjx002.089","article-title":"Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies","volume":"11","author":"Li","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.14309\/00000434-201710001-00658","article-title":"Tolerability of ustekinumab in induction and maintenance for the treatment of Crohn's disease","volume":"112","author":"Loftus","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.14309\/00000434-201802001-00101","article-title":"Tolerability of ustekinumab in induction and maintenance for the treatment of Crohn's disease","volume":"113 (Suppl 1)","author":"Lofus","year":"2018","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0029|cit29","unstructured":"NCT01369355 A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab maintenance therapy in subjects with moderately to severely active Crohn's disease clinicaltrials.gov\/ct2\/show\/nct01369355"},{"issue":"10 A","key":"10.1002\/14651858.CD012804.pub2-BIB0030|cit30","first-page":"S73","article-title":"Reduced healthcare costs of Crohn's disease-related hospitalizations and surgeries in patients initiated with ustekinumab in the im-uniti study","volume":"24","author":"Obando","year":"2018","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/ecco-jcc\/jjw019.013","article-title":"A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12\/23p40 mab, in moderate-severe Crohn's disease refractory to anti-tumour necrosis factor alpha: UNITI-1","volume":"10","author":"Rutgeerts","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"4","key":"10.1002\/14651858.CD012804.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0033|cit33","first-page":"A44","article-title":"Efficacy of ustekinumab for induction and maintenance of endoscopic healing in patients with Crohn's disease","volume":"4","author":"Rutgeerts","year":"2016","journal-title":"United European Gastroenterology Journal"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0034|cit34","first-page":"S157","article-title":"A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn's disease patients: results from im-uniti","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","article-title":"A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12\/23p40 mab, in moderate-severe Crohn's disease refractory to anti-TFNalpha: UNITI-1","volume":"22","author":"Sandborn","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0036|cit36","first-page":"S982","article-title":"Assessment of serum C-reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate-severely active Crohn's disease: results from the IM UNITI maintenance study","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/ecco-jcc\/jjx002.009","article-title":"Long term efficacy and safety of ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years","volume":"11","author":"Sandborn","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1136\/gutjnl-2016-312388.56","article-title":"A PH3 randomised, multicenter, double-blind, placebo (PBO)-controlled study of ustekinumab (UST) maintenance therapy in moderate-severe Crohn's Disease (CD) PTS: results from IM-Uniti","volume":"65","author":"Sandborn","year":"2016","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.14309\/00000434-201610001-00605","article-title":"Endoscopic healing in induction and maintenance with ustekinumab in the phase 3 uniti Crohn's disease program","volume":"111","author":"Sandborn","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0040|cit40","first-page":"A22","article-title":"Long term efficacy and safety of ustekinumab for Crohn's disease: results from im-uniti long-term extension through 2 years","volume":"66 (Suppl 2)","author":"Sandborn","year":"2017","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1016\/S0016-5085(17)32105-4","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease: results from im-uniti long-term extension through two years","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012804.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012804.pub2-BIB0043|cit43","first-page":"A121","article-title":"Efficacy and safety of ustekinumab for Crohn's disease: results from IM-uniti long-term extension through 3 years","volume":"6","author":"Sandborn","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/ecco-jcc\/jjy222.467","article-title":"Efficacy of ustekinumab in Crohn's disease at maintenance Week 56: IM-UNITI study","volume":"13","author":"Sandborn","year":"2019","journal-title":"Journal of Crohn's and Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0045|cit45","first-page":"s16","article-title":"Efficacy of ustekinumab in Crohn's disease at maintenance week 56: IM-UNITI study","volume":"25","author":"Sandborn","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0016-5085(18)31567-1","article-title":"Reduced rates of Crohn's-related surgeries, hospitalizations and alternate biologic initiation with ustekinumab in the Im-Uniti study through 2 years","volume":"154","author":"Sandborn","year":"2018","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0047|cit47","first-page":"S1097","article-title":"Immunogenicity of ustekinumab in patients with Crohn's disease: results from the Im-Uniti study","volume":"156","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0048|cit48","first-page":"A23","article-title":"Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn's disease patients: results from IM-UNITI maintenance study","volume":"66 (Supplement","author":"Sands","year":"2017","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0049|cit49","first-page":"S302","article-title":"Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn's disease patients: results from the im-uniti maintenance study","volume":"111","author":"Sands","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0050|cit50","first-page":"A2","article-title":"Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn's disease patients: results from the IM-UNITI maintenance study","volume":"4","author":"Sands","year":"2016","journal-title":"United European Gastroenterology Journal"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S0016-5085(18)31601-9","article-title":"Combined clinical and biological response (concomitant CRP and fecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn's disease studies","volume":"154","author":"Sands","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012804.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ecco-jcc\/jjy055","article-title":"The effects of ustekinumab on health-related quality of life in patients with moderate to severe Crohn's disease","volume":"12","author":"Sands","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"issue":"4","key":"10.1002\/14651858.CD012804.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S1004","DOI":"10.1016\/S0016-5085(16)33398-4","article-title":"Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn's disease: results from the uniti and IMUNITI phase 3 clinical trials","volume":"150","author":"Sands","year":"2016","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S1099","DOI":"10.1016\/S0016-5085(19)39710-0","article-title":"Association of ustekinumab serum concentrations and perianal fistula resolution in the Crohn's disease Uniti program","volume":"156","author":"Sands","year":"2019","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0055|cit55","first-page":"S457-8","article-title":"Briakinumab (anti-interleukin 12\/23p40, ABT874) for treatment of Crohn's disease","volume":"105","author":"Panaccione","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012804.pub2-BIB0056|cit56","first-page":"1329","article-title":"Briakinumab for treatment of Crohn's disease: results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0057|cit57","unstructured":"EUCTR2008-000649-77-FR A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ustekinumab therapy in subjects with moderately to severely active Crohn\u2019s disease previously treated with TNF antagonist therapy\u2014CERTIFI who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-000649-77-FR"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Feagan B Gasink C Gao L Blank M Johanns J Guzzo C A multicenter, randomized, double-blind, placebo-controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL-12\/23P40, in patients with moderately to severely active Crohn's disease: results through week 36 from the certifi trial American Journal Of Gastroenterology 2011 S463","DOI":"10.14309\/00000434-201110002-01227"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1873-9946(12)60320-1","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"6","author":"Feagan","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0060|cit60","unstructured":"NCT00771667 A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ustekinumab therapy in subjects with moderately to severely active Crohn's disease previously treated with TNF antagonist therapy clinicaltrials.gov\/ct2\/show\/NCT00771667"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0016-5085(11)60443-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase2b study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the Certifi trial","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD012804.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012804.pub2-BIB0063|cit63","first-page":"A490","article-title":"Pharmacokinetics and exposure-response relationship of ustekinumab, a human monoclonal antibody to interleukin 12\/23 in patients with moderate-to-severe Crohn's disease","volume":"134","author":"Fasanmade","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti\u2013Interleukin-12 antibody for active Crohn\u2019s disease","volume":"351","author":"Mannon","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012804.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ibd.21159","article-title":"Randomized, double-blind, placebo-controlled trial of the oral interleukin-12\/23 inhibitor apilimod mesylate for treatment of active Crohn's disease","volume":"16","author":"Sands","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0066|cit66","unstructured":"EUCTR2017-004209-41-DE A phase 3b, multicenter, randomized, blinded, active-controlled study to compare the efficacy and safety of ustekinumab to that of adalimumab in the treatment of biologic na\u00efve subjects with moderately-to-severely active Crohn\u2019s disease\u2014SEAVUE: safety and efficacy of adalimumab versus ustekinumab for one year who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-004209-41-DE"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0067|cit67","unstructured":"NCT03464136 A phase 3b, multicenter, randomized, blinded, active-controlled study to compare the efficacy and safety of ustekinumab to that of adalimumab in the treatment of biologic na\u00efve subjects with moderately-to-severely active Crohn's disease clinicaltrials.gov\/ct2\/show\/nct03464136"},{"issue":"7","key":"10.1002\/14651858.CD012804.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","volume":"29","author":"Benson","year":"2011","journal-title":"Nature Biotechnology"},{"issue":"6","key":"10.1002\/14651858.CD012804.pub2-BIB0069|cit69","first-page":"535","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"InMAbs"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0070|cit70","unstructured":"Crohn's Colitis Canada (CCC) Impact of inflammatory bowel disease in Canada crohnsandcolitis.ca\/Crohns_and_Colitis\/documents\/reports\/2018-Impact-Report-LR.pdf"},{"issue":"3","key":"10.1002\/14651858.CD012804.pub2-BIB0071|cit71","first-page":"216","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"InMAbs"},{"issue":"1","key":"10.1002\/14651858.CD012804.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012804.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012804.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: causative factors and clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD012804.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: a key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Annals of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD012804.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD012804.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/ajg.2011.296","article-title":"Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012804.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0016-5085(99)70392-6","article-title":"Anti\u2013interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice","volume":"117","author":"Fuss","year":"1999","journal-title":"Gastroenterology"},{"issue":"7650","key":"10.1002\/14651858.CD012804.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9317","key":"10.1002\/14651858.CD012804.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012804.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"7414","key":"10.1002\/14651858.CD012804.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0083|cit83","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"11","key":"10.1002\/14651858.CD012804.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007572.pub3","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","author":"MacDonald","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012804.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"Journal of Experimental Medicine"},{"issue":"9625","key":"10.1002\/14651858.CD012804.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"35","key":"10.1002\/14651858.CD012804.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.3748\/wjg.v12.i35.5606","article-title":"Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication","volume":"12","author":"Peluso","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012804.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/fg.2009.000174","article-title":"Optimising use of thiopurines in inflammatory bowel disease","volume":"1","author":"Raj","year":"2010","journal-title":"Frontline Gastroenterology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0089|cit89","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 2014"},{"issue":"3","key":"10.1002\/14651858.CD012804.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0091|cit91","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012804.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012804.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"16","key":"10.1002\/14651858.CD012804.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1097\/MD.0000000000003417","article-title":"Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-alpha independent Crohn disease","volume":"95","author":"Steenholdt","year":"2016","journal-title":"Medicine"},{"issue":"15","key":"10.1002\/14651858.CD012804.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012804.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ni1092","article-title":"NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses","volume":"5","author":"Watanabe","year":"2004","journal-title":"Nature Immunology"},{"key":"10.1002\/14651858.CD012804.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1002\/14651858.CD012804.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn's disease","volume":"97","author":"Yang","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012804.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1590\/1806-9282.65.4.554","article-title":"Crohn's disease\u2014treatment with biological medication","volume":"65","author":"Zaltman","year":"2019","journal-title":"Revista da Associacao Medica Brasileira"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012804.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T07:03:35Z","timestamp":1708844615000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012804.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":99,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012804.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]}}}